Do you want to read an article? Please log in or register.
Statin therapy for primary prevention in the elderly and its association with new-onset diabetes, cardiovascular events and all-cause mortality
Diabetes - General
COMMENTED
Related content
Type 2 Diabetes
Delays in Anti-Hyperglycemic Therapy Initiation and Intensification are Associated with Cardiovascular Events, Heart Failure Hospitalizations, and All-Cause Mortality
Diabet Med.
Nichols GA, Romo-LeTourneau V, Vupputuri S, Thomas SM
doi: 10.1111/dme.13941.
COMMENTED
Diabetes - GeneralGlycemic Control
The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes
Diabetes Care.
Lee AK, Warren B, Lee CJ, McEvoy JW, Matsushita K, Huang ES, Sharrett AR, Coresh J, Selvin E
doi: 10.2337/dc17-1669.
Type 2 Diabetes
Arterial stiffness as a risk factor for cardiovascular events and all-cause mortality in people with Type 2 diabetes
Diabet Med.
Sharif S, Visseren FLJ, Spiering W, de Jong PA, Bots ML, Westerink J; SMART study group
doi: 10.1111/dme.13954.
Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial
JAMA Intern Med.
Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS; ALLHAT Collaborative Research Group
doi: 10.1001/jamainternmed.
Diabetes - General
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Lancet Diabetes Endocrinol.
Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR
doi: 10.1016/
Diabetes - GeneralType 2 Diabetes
Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial
Diabetes Care.
Basu S, Raghavan S, Wexler DJ, Berkowitz SA
doi: 10.2337/dc17-2252.
Diabetes - GeneralType 2 Diabetes
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
Diabetologia.
Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B
doi: 10.1007/s00125-018-4644-9.
COMMENTED
Type 2 Diabetes
Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.2337/dc19-2535.
COMMENTED
Lipids
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Lancet.
Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S
doi: 10.1016/S0140-